CN1306958C - 用于免疫受损人群的糖结合物疫苗 - Google Patents

用于免疫受损人群的糖结合物疫苗 Download PDF

Info

Publication number
CN1306958C
CN1306958C CNB028184238A CN02818423A CN1306958C CN 1306958 C CN1306958 C CN 1306958C CN B028184238 A CNB028184238 A CN B028184238A CN 02818423 A CN02818423 A CN 02818423A CN 1306958 C CN1306958 C CN 1306958C
Authority
CN
China
Prior art keywords
type
vaccine
antigens
immunologic function
involved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028184238A
Other languages
English (en)
Chinese (zh)
Other versions
CN1638794A (zh
Inventor
A·I·法托姆
R·B·纳索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxart Inc
Original Assignee
Nabi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Inc filed Critical Nabi Inc
Publication of CN1638794A publication Critical patent/CN1638794A/zh
Application granted granted Critical
Publication of CN1306958C publication Critical patent/CN1306958C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CNB028184238A 2001-09-19 2002-09-19 用于免疫受损人群的糖结合物疫苗 Expired - Lifetime CN1306958C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/955,585 US20030113350A1 (en) 2001-09-19 2001-09-19 Glycoconjugate vaccines for use in immune-compromised populations
US09/955,585 2001-09-19

Publications (2)

Publication Number Publication Date
CN1638794A CN1638794A (zh) 2005-07-13
CN1306958C true CN1306958C (zh) 2007-03-28

Family

ID=25497036

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028184238A Expired - Lifetime CN1306958C (zh) 2001-09-19 2002-09-19 用于免疫受损人群的糖结合物疫苗

Country Status (11)

Country Link
US (2) US20030113350A1 (enExample)
EP (1) EP1427442A4 (enExample)
JP (2) JP2005515237A (enExample)
KR (3) KR101090529B1 (enExample)
CN (1) CN1306958C (enExample)
CA (1) CA2460749C (enExample)
EA (1) EA006602B1 (enExample)
MX (1) MXPA04002624A (enExample)
NZ (1) NZ548453A (enExample)
WO (1) WO2003061558A2 (enExample)
ZA (1) ZA200402185B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100217772B1 (ko) * 1996-09-03 1999-09-01 최진호 조명기기의 램프 과열방지 장치 및 방법
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
PT1565478T (pt) 2002-11-12 2017-11-14 The Brigham And Women`S Hospital Inc Vacina de polissacáridos para infeções estafilocócicas
WO2004050846A2 (en) * 2002-12-02 2004-06-17 Biosynexus Incorporated Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
JP5102487B2 (ja) * 2003-03-07 2012-12-19 ワイス・ホールディングズ・コーポレイション 院内感染に対する免疫化のための多糖ブドウ球菌表面付着因子キャリアタンパク質接合体
AU2011265368B9 (en) * 2004-09-22 2012-11-29 Biosynexus Incorporated Immunogenic composition
RU2402347C2 (ru) * 2004-09-22 2010-10-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
AU2005324448A1 (en) * 2005-01-10 2006-07-20 Glaxosmithkline Biologicals Sa Method of treating Staphylococcus aureus infection
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
FR2884830A1 (fr) 2005-04-25 2006-10-27 Sanofi Pasteur Sa Procede de production de souches de staphylococcus aureus surproductrices
PL3006458T3 (pl) * 2005-07-29 2018-05-30 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości
WO2007113222A2 (en) * 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
FR2899110A1 (fr) * 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
JP5658564B2 (ja) * 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
KR101573648B1 (ko) 2008-07-21 2015-12-01 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
MX373250B (es) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
BR112012010223A2 (pt) 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
AU2010342872B2 (en) * 2010-01-19 2014-09-25 Universitatsklinikum Freiburg Enterococcal cell wall components and antibacterial use thereof
SG186290A1 (en) 2010-07-02 2013-01-30 Univ Chicago Compositions and methods related to protein a (spa) variants
CN102565354A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539726A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539708A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539702A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102565332A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102565336A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539704A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2014013375A1 (en) 2012-07-16 2014-01-23 Pfizer Inc. Saccharides and uses thereof
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
WO2016091904A1 (en) 2014-12-10 2016-06-16 Glaxosmithkline Biologicals Sa Method of treatment
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
KR20220079534A (ko) * 2019-08-27 2022-06-13 알로펙스, 인크. 항미생물 백신 조성물
WO2023133143A1 (en) * 2022-01-05 2023-07-13 Bluewillow Biologics, Inc. Intranasal polysaccharide conjugate nanoemulsion vaccines and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Effect of conjugation methodology, carrier protein, andadjuvants on the immune response to Staphylococcus aureuscapsular polysaccharides Fattom,.A et al,Vaccine,Vol.13 No.14 1995 *
Safety and immunogenicity of Staphylococcus aureus type 5capsular polysaccharide-Pseudomonas aeruginosarecombinant exoprotein A conjugate vaccine in patients onhemodialysis Welch,.P.G et al,J.Am.Soc.Nephrol.,Vol.7 No.2 1996 *

Also Published As

Publication number Publication date
WO2003061558A2 (en) 2003-07-31
CN1638794A (zh) 2005-07-13
ZA200402185B (en) 2005-06-29
KR101214766B1 (ko) 2012-12-24
CA2460749C (en) 2012-10-23
WO2003061558A3 (en) 2003-09-12
KR101090529B1 (ko) 2011-12-08
EA200400448A1 (ru) 2004-12-30
EP1427442A4 (en) 2006-06-21
WO2003061558A9 (en) 2004-06-10
US20030113350A1 (en) 2003-06-19
CA2460749A1 (en) 2003-07-31
KR20080089527A (ko) 2008-10-06
KR20040070331A (ko) 2004-08-07
US20060188518A1 (en) 2006-08-24
NZ548453A (en) 2007-07-27
EP1427442A2 (en) 2004-06-16
MXPA04002624A (es) 2005-02-17
JP2010265293A (ja) 2010-11-25
JP2005515237A (ja) 2005-05-26
US7449189B2 (en) 2008-11-11
KR20100044265A (ko) 2010-04-29
EA006602B1 (ru) 2006-02-24

Similar Documents

Publication Publication Date Title
CN1306958C (zh) 用于免疫受损人群的糖结合物疫苗
Wessels et al. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine
Devi et al. Antibodies to poly [(2----8)-alpha-N-acetylneuraminic acid] and poly [(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1.
AU2005316864B2 (en) Glycoconjugate vaccines containing peptidoglycan
EA037500B1 (ru) Способы и композиции для иммунной защиты против внекишечной патогенной e. coli
JP2009227680A (ja) 腸球菌抗原およびワクチン
JP2631035B2 (ja) 多糖類−タンパク質複合体
US20120231086A1 (en) Protein matrix vaccines of improved immunogenicity
EP4512419A1 (en) Polyvalent pneumococcal polysaccharide conjugate vaccine component and application thereof
Cross Hit ‘em where it hurts: gram-negative bacterial lipopolysaccharide as a vaccine target
WO2014195880A1 (en) An isolated immunogenic bacterial antigen and its use in the prevention and treatment of infections caused by gram-negative bacteria
Cryz Jr et al. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines
Waite et al. Capsular polysaccharide conjugate vaccines against contagious bovine pleuropneumonia: immune responses and protection in mice
Wang et al. Development of carbohydrate based next-generation anti-pertussis vaccines
Salo et al. Salicylate-enhanced exposure of Klebsiella pneumoniae subcapsular components
AU2002365253B2 (en) Glycoconjugate vaccines for use in immune-compromised populations
CN101443454A (zh) 多价脑膜炎球菌衍生化的多糖-蛋白质缀合物和疫苗
Henriksen et al. Vaccination with Protein‐Conjugated and Native Type 3 Capsular Polysaccharide in an Ethanol‐Fed Rat Model of Pneumococcal Pneumonia
Pon et al. Carbohydrate‐Based Antibacterial Vaccines
NZ531647A (en) Glycoconjugate vaccines for use in immune-compromised populations against Staphylococcal and Enterococcal infections
RU2780425C2 (ru) Композиции neisseria meningitidis и способы
AU2002365253A1 (en) Glycoconjugate vaccines for use in immune-compromised populations
Liao et al. Characterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhi
Byrd Development of conjugate vaccines to protect pigs against swine pleuropneumonia induced by Actinobacillus pleuropneumoniae
Medero et al. Vaccines against Bacterial Pathogens: A General Overview

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: GLAXOSMITHKLINE BIOLOGICALS COMPANY

Free format text: FORMER OWNER: NABI

Effective date: 20100809

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: MARYLAND STATE, USA TO: RICKSON SARTRE, BELGIUM

TR01 Transfer of patent right

Effective date of registration: 20100809

Address after: Belgium Sutter Rixon

Patentee after: NABI BIOPHARMACEUTICALS

Address before: American Maryland

Patentee before: NABI Biopharmaceuticals

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20070328